Phathom Pharmaceuticals, Inc.
PHATPhathom Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to the development and commercialization of novel treatments for gastrointestinal diseases.
Earnings
Q3 2026 report
October 29, 2026Next report
Date not yet announcedValuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to the development and commercialization of novel treatments for gastrointestinal diseases. The company's core value proposition centers on vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that provides a potent and rapid alternative to traditional proton pump inhibitors. Their primary focus is addressing significant unmet needs in acid-related disorders such as GERD and H. pylori infections.
Phathom holds a first-mover advantage as the provider of the only FDA-approved PCAB in the United States, positioning it as a premium alternative to the established but often inadequate generic PPI market.
FAQ
- What is Phathom Pharmaceuticals, Inc.'s market cap?
- Phathom Pharmaceuticals, Inc. (PHAT) has a market capitalization of $505.6M and trades on NASDAQ.
- What is Phathom Pharmaceuticals, Inc.'s revenue and profitability?
- Phathom Pharmaceuticals, Inc. generated $274.9M in trailing twelve-month revenue with a net loss of $83.0M, representing a net margin of -30.2%. Gross margin stands at 80.7%. The latest reported period is Q3 2026.
- Who are Phathom Pharmaceuticals, Inc.'s competitors?
- Phathom Pharmaceuticals, Inc.'s key competitors include Vanda Pharmaceuticals Inc., Opko Health Inc., Verastem, Inc., and others. These companies compete in similar markets and product categories.
- Who does Phathom Pharmaceuticals, Inc. partner with?
- Phathom Pharmaceuticals, Inc.'s notable partners include Takeda Pharmaceutical Company Limited, Evonik Operations GmbH, Catalent Pharma Solutions, LLC, and others.
- Where is Phathom Pharmaceuticals, Inc. headquartered?
- Phathom Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 112 people. It has been publicly traded since 2019.
